ADVFN US – Market Content Editor
-
Relay Therapeutics shares climb after Oppenheimer lifts rating
Shares of Relay Therapeutics Inc (NASDAQ:RLAY) jumped 5.8% in premarket trading on Monday after Oppenheimer upgraded the biotechnology company to Outperform from Perform and set a new price target of $14.00. Analyst Matt Biegler pointed to potential near-term catalysts for Relay’s mutant-selective inhibitor zovegalisib, particularly ahead of the upcoming VIKTORIA-1 clinical trial results for rival…
-
Revolution Medicines shares slide after Merck reportedly walks away from takeover talks
Merck & Company Inc (NYSE:MRK) has reportedly ended discussions to acquire Revolution Medicines Inc (NASDAQ:RVMD) after the two sides failed to agree on valuation, according to the Wall Street Journal, citing people familiar with the situation. The talks had centered on a potential transaction that could have valued the oncology-focused biotech at around $30 billion.…
-
CoreWeave shares jump 10% after $2 billion NVIDIA investment deepens AI alliance
CoreWeave (NASDAQ:CRWV) shares climbed 10% on Monday after NVIDIA (NASDAQ:NVDA) disclosed a $2 billion equity investment aimed at strengthening and expanding the companies’ artificial intelligence infrastructure partnership. As part of the deal, NVIDIA acquired CoreWeave Class A common shares at $87.20 apiece. The investment sits within a broader strategic collaboration focused on accelerating the development…
-
Sarepta posts encouraging three-year data for Duchenne gene therapy
Sarepta Therapeutics Inc. (NASDAQ:SRPT) released three-year follow-up results from its EMBARK study, showing that its gene therapy ELEVIDYS slowed functional decline in ambulatory patients with Duchenne muscular dystrophy. The analysis covered 52 patients who received ELEVIDYS at an average age of nine. After three years, treated patients maintained average scores on the North Star Ambulatory…
-
MannKind shares climb after FDA clears revised Afrezza prescribing label
MannKind Corporation (NASDAQ:MNKD) shares gained 3.5% on Monday after the company said the U.S. Food and Drug Administration has approved changes to the prescribing information for its Afrezza inhaled insulin. The revised label is intended to give healthcare professionals more explicit guidance on initial dosing when switching patients from subcutaneous mealtime insulin—whether via multiple daily…
-
Steel Dynamics stock advances after Q4 profit tops forecasts
Steel Dynamics, Inc. (NASDAQ:STLD) shares climbed 2.6% after the company reported fourth-quarter earnings that came in ahead of market expectations, even as revenue missed consensus estimates. The steelmaker delivered net income of $266 million for the quarter, equal to $1.82 per diluted share, beating analysts’ forecasts of $1.69 per share. Quarterly revenue totaled $4.4 billion,…
-
IonQ shares edge higher on plan to buy SkyWater Technology
IonQ (NYSE:IONQ) shares rose 1.65% on Monday, while SkyWater Technology (NASDAQ:SKYT) jumped 8%, after IonQ unveiled plans to acquire the semiconductor manufacturer in a cash-and-stock transaction valued at roughly $1.8 billion. The proposed deal prices SkyWater at $35.00 per share, implying a 38% premium to its 30-day volume-weighted average price as of January 23. Under…
-
Santacruz Silver shares climb as silver tops $110 and output rebounds
Shares of Santacruz Silver Mining Ltd. (NASDAQ:SCZM) gained 7% on Monday after silver prices surged past $110 per ounce and the company released its fourth-quarter 2025 production update. During Q4 2025, the miner delivered 3.74 million silver equivalent ounces, marking a 9% increase compared with the prior quarter. Silver output rose 8% quarter on quarter…
-
Eaton targets Q1 2027 spin-off of Mobility Group
Eaton Corporation (NYSE:ETN) said it intends to separate its Vehicle and eMobility operations into a standalone, publicly listed company, with the transaction expected to be completed by the end of the first quarter of 2027. The Dublin-headquartered power management group said the move will sharpen its focus on its Electrical and Aerospace segments, which it…
-
Winter storm Fern expected to weigh heavily on U.S. growth in Q1
Winter storm Fern is likely to deliver a notable, though temporary, blow to U.S. economic activity, with Bank of America estimating a drag of between 0.5 and 1.5 percentage points on first-quarter GDP growth. In a client note, BofA analyst Aditya Bhave said the bank is drawing lessons from Winter Storm Viola in 2021, arguing…